Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
16 hedge funds and large institutions have $67.2M invested in Calliditas Therapeutics AB American Depositary Shares in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 11 closing their positions.
12% less capital invested
Capital invested by funds: $76.2M → $67.2M (-$9.03M)
30% less funds holding
Funds holding: 23 → 16 (-7)
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.82M |
| 2 |
BCM
Burrage Capital Management
Boston,
Massachusetts
|
+$257K |
| 3 |
Jane Street
New York
|
+$29K |
| 4 |
BlackRock
New York
|
+$27.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$19.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.83M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.48M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.32M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.48M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.14M |
CALT Hedge Fund Activity: Q3 2020 in Review
16 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q3 2020, worth a combined $67.2M — down 12% from $76.2M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CALT and 4 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 2 added.
The largest buyer was Logos Global Management, adding an estimated $5.82M. The largest seller was OrbiMed, cutting an estimated $4.83M.
- 16 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q3 2020, down from 23 in Q2 2020.
- Funds reported $67.2M of Calliditas Therapeutics AB American Depositary Shares stock for Q3 2020, down 12% quarter-over-quarter.
- 4 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q3 2020 and 11 closed out, a net change of -7 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q3 2020 was Logos Global Management, an estimated $5.82M added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q3 2020 was OrbiMed, an estimated $4.83M sold.
Based on aggregated 13F filings for Q3 2020.